Entest Biomedical Stock Analysis

Entest Pink Sheet Analysis Notes

The company recorded a loss per share of 0.0. Entest Biomedical had not issued any dividends in recent years. The entity had 1:150 split on the 27th of July 2015. It intends to seek business opportunities to review and analyze for purposes of effecting a merger, acquisition, or other business combination with an operating company business. Entest Group, Inc. was founded in 2008 and is based in Shenzhen, China. Entest is traded on OTC Exchange in the United States.The quote for Entest Biomedical is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. To learn more about Entest Biomedical call Peiwen Yu at 86 13709631109.

Entest Biomedical Investment Alerts

Entest Market Capitalization

The company currently falls under 'Nano-Cap' category with a current market capitalization of 127.84 K. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Entest Biomedical's market, we take the total number of its shares issued and multiply it by Entest Biomedical's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Technical Drivers

As of the 10th of February, Entest Biomedical shows the Mean Deviation of 2.69, standard deviation of 11.08, and Variance of 122.73. Entest Biomedical technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.

Entest Biomedical Price Movement Analysis

Entest Biomedical Outstanding Bonds

Entest Biomedical Predictive Daily Indicators

Entest Biomedical Forecast Models

Entest Biomedical's time-series forecasting models are one of many Entest Biomedical's pink sheet analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Entest Biomedical's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Entest Biomedical Debt to Cash Allocation

Entest Biomedical currently holds 38.29 K in liabilities with Debt to Equity (D/E) ratio of 27.3, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Entest Biomedical has a current ratio of 0.04, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Entest Biomedical until it has trouble settling it off, either with new capital or with free cash flow. So, Entest Biomedical's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Entest Biomedical sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Entest to invest in growth at high rates of return. When we think about Entest Biomedical's use of debt, we should always consider it together with cash and equity.

Entest Biomedical Assets Financed by Debt

Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Entest Biomedical's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Entest Biomedical, which in turn will lower the firm's financial flexibility.

Entest Biomedical Corporate Bonds Issued

Pink Sheet analysis is the technique used by a trader or investor to examine and evaluate how Entest Biomedical prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Entest shares will generate the highest return on investment. We also built our pink sheet analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Pink Sheet such as Entest Biomedical. By using and applying Entest Pink Sheet analysis, traders can create a robust methodology for identifying Entest entry and exit points for their positions.

When running Entest Biomedical's price analysis, check to measure Entest Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Entest Biomedical is operating at the current time. Most of Entest Biomedical's value examination focuses on studying past and present price action to predict the probability of Entest Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Entest Biomedical's price. Additionally, you may evaluate how the addition of Entest Biomedical to your portfolios can decrease your overall portfolio volatility.